ALFA Filings
Every announcement, straight from the exchange
Every Lupin product launch announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements
Lupin Limited launched Formoflo-G® MDI, the world's first fixed-dose triple combination inhaler for COPD management in India. This follows approval from the Drug Controller General of India.
Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.
Lupin Limited has launched Sugammadex Injection in the United States following U.S. FDA approval. The product is a bioequivalent to Merck's Bridion® for reversing neuromuscular blockade.
Lupin Limited has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. This follows approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA). The product is a generic version of Xigduo XR, expanding Lupin's anti-diabetic portfolio in the U.S. market.
Lupin Limited has launched Dapagliflozin Tablets (5 mg and 10 mg) in the United States. The product is a bioequivalent generic version of Farxiga®, following approval from the U.S. FDA. This launch expands Lupin's anti-diabetic portfolio in the U.S. market, leveraging its strong position across multiple therapy areas.